AU740874B2 - Method for optimizing retinal and optic nerve health - Google Patents

Method for optimizing retinal and optic nerve health Download PDF

Info

Publication number
AU740874B2
AU740874B2 AU81622/98A AU8162298A AU740874B2 AU 740874 B2 AU740874 B2 AU 740874B2 AU 81622/98 A AU81622/98 A AU 81622/98A AU 8162298 A AU8162298 A AU 8162298A AU 740874 B2 AU740874 B2 AU 740874B2
Authority
AU
Australia
Prior art keywords
adrenergic receptor
composition
carbonic anhydrase
concentration
blocking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81622/98A
Other languages
English (en)
Other versions
AU8162298A (en
Inventor
Michael F Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800449.2A external-priority patent/GB9800449D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU8162298A publication Critical patent/AU8162298A/en
Application granted granted Critical
Publication of AU740874B2 publication Critical patent/AU740874B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU81622/98A 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health Ceased AU740874B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5083597P 1997-06-26 1997-06-26
US60/050835 1997-06-26
GB9800449 1998-01-09
GBGB9800449.2A GB9800449D0 (en) 1998-01-09 1998-01-09 Method for optimizing retinal and optic nerve health
PCT/US1998/013038 WO1999000133A1 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Publications (2)

Publication Number Publication Date
AU8162298A AU8162298A (en) 1999-01-19
AU740874B2 true AU740874B2 (en) 2001-11-15

Family

ID=26312917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81622/98A Ceased AU740874B2 (en) 1997-06-26 1998-06-22 Method for optimizing retinal and optic nerve health

Country Status (5)

Country Link
EP (1) EP1024810A4 (ja)
JP (1) JP2002506461A (ja)
AU (1) AU740874B2 (ja)
CA (1) CA2294343A1 (ja)
WO (1) WO1999000133A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
DE60003445T2 (de) 1999-11-01 2003-12-24 Alcon, Inc. Pharmazeutische zusammensetzungen ein fluorchinolonantibiotikum und xanthangummi enthaltend
DK1305033T3 (da) 2000-07-28 2005-01-31 Alcon Inc Farmaceutiske pæaparater indeholdende tobramycin og xanthangummi
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP4948176B2 (ja) * 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
DE602006011330D1 (de) 2005-07-11 2010-02-04 Senju Pharma Co Augentropfenzubereitung mit xanthangummi und terpenoid
EP2002841A4 (en) 2006-03-23 2009-04-15 Senju Pharma Co OPHTHALMIC COMPOSITION WITH XANTHANGUMMI AND GLUCOSE
JP2010513262A (ja) 2006-12-15 2010-04-30 ニコックス エス エイ カルボニックアンヒドラーゼ阻害剤誘導体
US8222156B2 (en) 2006-12-29 2012-07-17 Lam Research Corporation Method and apparatus for processing a substrate using plasma
JP5305710B2 (ja) * 2008-03-31 2013-10-02 株式会社ニデック ドルゾラミド塩酸塩点眼液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE9059T1 (de) * 1980-01-28 1984-09-15 Merck & Co. Inc. Ophthalmische kohlensaure anhydrase-inhibitoren enthaltende einlagen zur verringerung intraokularer hypertension.
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5789435A (en) * 1995-05-22 1998-08-04 Advanced Research And Technology Institute Method to increase retinal and optical nerve head blood flow velocity in order to preserve sight

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378703A (en) * 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
EP1024810A1 (en) 2000-08-09
JP2002506461A (ja) 2002-02-26
CA2294343A1 (en) 1999-01-07
EP1024810A4 (en) 2003-06-11
WO1999000133A1 (en) 1999-01-07
AU8162298A (en) 1999-01-19

Similar Documents

Publication Publication Date Title
US6949518B1 (en) Methods for treating macular degeneration with topiramate
AU715223B2 (en) Ophthalmic compositions containing a carbonic anhydrase inhibitor and xanthan gum
EP0227494B1 (en) Pharmaceutical composition of the type which undergoes liquid-gel phase transition
US4476140A (en) Composition and method for treatment of glaucoma
AU740874B2 (en) Method for optimizing retinal and optic nerve health
JPH11504330A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
JPH08509205A (ja) β−シクロデキストリン誘導体及び治療剤を含んだ眼のための局所組成物
US5314909A (en) Use of non-steroidal antiiflammatory agents in macular degeneration
US5049587A (en) Ophthalmic solution for intraocular pressure adjustment
JP2005516017A (ja) 向上した薬物動態特性を示す医薬コンジュゲート
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US6156785A (en) Method for increasing oxygen tension in the optic nerve and retina
KR100193406B1 (ko) 근시의 예방 및 치료용 조성물
AU746893B2 (en) Method for increasing oxygen tension in the optic nerve and retina
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
EP1633353A1 (en) Composition and method for treating macular disorders
KR0159640B1 (ko) 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형
CA2005753A1 (en) Angiotensin converting enzyme inhibitors in the treatment of glaucoma

Legal Events

Date Code Title Description
SREP Specification republished
TH Corrigenda

Free format text: IN VOL 15, NO 41, PAGE(S) 9131 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX IN THE NAME OF MERCK AND CO., INC., SERIAL NO. 740874, INID (72), AMEND THE INVENTOR TO READ SUGRUE, M.F.

FGA Letters patent sealed or granted (standard patent)